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Abstract
Mitochondria are best known as the essential intracellular organelles that host the homeostasis required for cellular survival,
but they also have relevance in diverse disease-related conditions, including Alzheimer’s disease (AD). Amyloid b (Ab) peptide
is the key molecule in AD pathogenesis, and has been highlighted in the implication of mitochondrial abnormality during the
disease progress. Neuronal exposure to Ab impairs mitochondrial dynamics and function. Furthermore, mitochondrial Ab
accumulation has been detected in the AD brain. However, the underlying mechanism of how Ab affects mitochondrial
function remains uncertain, and it is questionable whether mitochondrial Ab accumulation followed by mitochondrial
dysfunction leads directly to neuronal toxicity. This study demonstrated that an exogenous Ab1–42 treatment, when applied to
the hippocampal cell line of mice (specifically HT22 cells), caused a deleterious alteration in mitochondria in both morphology
and function. A clathrin-mediated endocytosis blocker rescued the exogenous Ab1–42-mediated mitochondrial dysfunction.
Furthermore, the mitochondria-targeted accumulation of Ab1–42 in HT22 cells using Ab1–42 with a mitochondria-targeting
sequence induced the identical morphological alteration of mitochondria as that observed in the APP/PS AD mouse model
and exogenous Ab1–42-treated HT22 cells. In addition, subsequent mitochondrial dysfunctions were demonstrated in the
mitochondria-specific Ab1–42 accumulation model, which proved indistinguishable from the mitochondrial impairment
induced by exogenous Ab1–42-treated HT22 cells. Finally, cellular toxicity was directly induced by mitochondria-targeted Ab1–
42 accumulation, which mimics the apoptosis process in exogenous Ab1–42-treated HT22 cells. Taken together, these results
indicate that mitochondria-targeted Ab1–42 accumulation is the necessary and sufficient condition for Ab-mediated
mitochondria impairments, and leads directly to cellular death rather than along with other Ab-mediated signaling alterations.
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Introduction
Mitochondria are of great importance in cellular metabolism,
survival, differentiation and homeostasis. Mitochondria are
involved not only in energy production, but also in other cellular
activity, including calcium buffering, signal cascade, apoptosis
induction and so forth [1]. The structure of mitochondria features
a double-membrane construction involving an outer and an inner
membrane. The outer membrane has voltage-dependent anionic
channels that enable small molecules to be permeable. The inner
membrane is the main barrier to metabolites and transporter
proteins, including the TOM/TIM protein complexes that help
transport protein across the inner membrane [2]. Additionally, the
mitochondrial inner membrane generates an ATP energy source
using a respiratory chain (electron transport chain) with complexes
I through V [3].
The homeostasis of mitochondria dynamics happens through a
repetitive fission and fusion process, so the size and number of
mitochondria is variable according to the cellular energy demands
and metabolic states. Ab influences the fission/fusion dynamic by
altering the fission/fusion-related protein levels, increasing the
expression of mitochondria fission genes and decreasing that of
fusion genes [4]. The increased fission gene expression prompted
by Ab alters mitochondrial morphology through fragmentation,
resulting in a significantly increased number of mitochondria. The
morphology and motility of the mitochondria are highly related to
cytoskeletal elements, including neurofilaments and microtubule
proteins [5]. Ab (Ab 25–35) disturbs the axonal anterograde
transport and distribution of mitochondria in mouse hippocampal
neurons, which leads to synaptic degeneration [6].
The neuron is one of the cells most vulnerable to mitochondrial
damage, due to its high energy demands and sensitivity to reactive
oxygen species (ROS) and apoptosis. There have been numerous
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neurodegenerative diseases including Parkinson’s disease and AD,
mediated by oxidative stress [7,8,9,10]. Although amyloid plaque
is the hallmark of AD, consisting of extracellular aggregation of the
amyloid b peptide, the causative toxic event may occur within the
cell much earlier than the appearance of senile plaque. Moreover,
several lines of evidence show that Ab is generated intracellularly
in AD-related human brain regions, with the toxicity of
intracellular Ab preceding toxicity by senile plaque and neurofi-
brillary tangles [11]. Even in the absence of amyloid plaque, Ab1–
42 elicits synaptic toxicity in an amyloid plaque-independent
manner [12]. Regarding its localization in intracellular compart-
ments, Ab has been observed in mitochondria in transgenic mice
expressing human mutant amyloid precursor proteins (APPs),
possibly within the membrane or a membrane-associated
compartment [13,14]. The mitochondrial Ab distribution in the
brain region is parallel to areas affected by the AD pathological
progress in the murine model. Furthermore, Ab was associated
with mitochondria from AD patients compared to a cohort group
[15,16]. In an AD patient, mitochondrial destruction was reported
in various brain regions [17], including the severe disruption of
mitochondrial cristae, vacuole association with lipofuscin (symp-
tomatic of mitochondrial and lysosomal damage) and increased
mitochondrial DNA in pyramidal neurons within the hippocam-
pus [5,17].
Mitochondrial dysfunction seems to be one of the earliest signs
of the AD pathological process, because mitochondrial abnormal-
ity is detectable in neurons lacking neurofibrillary tangles. Early
deficits of synaptic mitochondria are detected in FAD mutant APP
transgenic mice, representing Ab accumulation within the
mitochondria prior to extracellular Ab deposition [18]. However,
the direct association of mitochondrial Ab accumulation with AD
pathology is uncertain. Furthermore, proof of a direct relationship
between mitochondria-specific Ab accumulation and AD-related
mitochondrial dysfunction leading to cellular toxicity remains
questionable. In this study we tested whether mitochondria-
targeted Ab1–42 accumulation, not existing in other cellular
compartments, could elicit the identical morphological alteration
and dysfunction in the mitochondria of an AD mouse model and
in AD-mimicking cell line conditions. Cellular toxicity caused by
mitochondria-specific Ab1–42 accumulation was compared to that
in the cellular model, induced by extracellular Ab1–42 treatments
that mimicked the AD pathological environment. This study used
Ab1–42—the main toxic species among various Ab peptides,
containing mitochondria targeting sequence—and multiple mea-
surements from mitochondrial functions to verify that the sole
mitochondria-specific accumulation of Ab1–42 is a sufficient
mechanism to cause the mitochondrial dysfunction that leads to
cellular toxicity and death.
Results
Morphological alteration of mitochondria in both in vivo
and in vitro AD models
In an attempt to characterize the mitochondrial changes in both
AD mice and cell line models, we investigated the morphological
alteration of the mitochondria in the cortex region of AbPP/PS1
double transgenic mice (10 month) and HT22 cells treated with
exogenous Ab1–42. Electron microscopy (EM) revealed that the
mitochondria in wild type mice showed intact, healthy structures
Figure 1. Morphological alteration of mitochondria in AbPP/PS1 mice brains and Ab1–42-treated HT22 cell line. A. Electron microscopic
(EM) image of mitochondria in wild type and AbPP/PS1 mice (10 months, cortex, scale bar: 2 mm) B. EM image of mitochondria in vehicle and Ab-
treated HT22 cells (yellow scale bar: 2 mm, white scale bar: 1 mm) C. Immunostaining of HSP60 in Ab1–42-treated HT22 cell line by different time period
of treatment (scale bar: 20 mm).
doi:10.1371/journal.pone.0034929.g001
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mitochondria of AbPP/PS1 double transgenic mice represented a
great deal of fragmentation, vacuoles and cristae disruption—the
definitive features of apoptosis. In addition, swelling drastically
increased mitochondrial sizes in AbPP/PS1 double transgenic
mice compared to those in wild type mice. These diverse
morphological alterations of the mitochondria suggest consider-
able mitochondrial dysfunctions in these cells.
To examine mitochondrial deterioration by AD-like condition
in cell line, HT22 cells were incubated with exogenous treatment
of 5 mMA b1–42 for 7 h and analyzed using EM. The results were
similar to those from previous observations of AbPP/PS1 double
transgenic mice, obtained in Ab1–42-treated HT22 cells, compared
to those from control cells with vehicle treatment. Specifically,
most of the mitochondria were swollen, exhibiting the disruption
of the inner membrane and cristae in Ab1–42-treated HT22 cells
(Fig. 1B). For further confirmation, we performed confocal
microscopy using immunofluorescence with antibodies to HSP60
(heat shock protein 60, as a mitochondrial marker) after a different
time period of treatment with 5 mMA b1–42. Intact rod-shaped
mitochondria started to fragmentize within 2 h of Ab1–42
treatment, representing shortened forms and finally displaying a
highly dispersed smear shape after 8 h of Ab1–42 treatment
(Fig. 1C), indicating mitochondrial fragmentation and dysfunction.
Mitochondrial dysfunction induced by exogenous Ab1–42
treatment in HT22 cells
Diverse functional assessments were performed to evaluate
mitochondrial function under excess Ab1–42 conditions. We
measured four parameters: the MTT [(3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide)] assay for mitochondrial
dehydrogenase activity; TMRM (Tetramethyl rhodamine methyl
ester) intensity for mitochondrial membrane potential; fluorescent
probe (CM-H2DCFDA) for ROS level and luciferase-based assay
for ATP generation, respectively. A significant impairment of all
four functional assessments occurred in Ab1–42-treated HT22 cells,
suggesting that the exogenous treatment of Ab1–42 induces
mitochondrial dysfunction (Fig. 2A–D). The presence of decreased
mitochondrial dehydrogenase activity, a reduction in ATP
generation, a breakdown of mitochondrial membrane potential
and increased ROS generation all certainly suggest the functional
impairment of mitochondria, along with morphological mito-
chondrial alterations (Figs. 1B and 1C) in HT22 cells by Ab1–42
and the possibility that mitochondria might be the major target
location for Ab1–42 to accumulate and affect inside the cell.
Endocytosis blocker inhibited Ab1–42-induced
mitochondrial impairments in both morphology and
function
Regarding the pathophysiological pathway of Ab1–42, we tested
whether Ab1–42 needs to enter the intracellular compartment in
order to elicit mitochondrial dysfunction. As Ab1–42 is known to
enter the intracellular compartment through clathrin-mediated
endocytosis, chlorpromazine, a well-known clathrin-mediated
endocytosis blocker, has been tested along with Ab1–42 to
investigate whether it inhibits the Ab1–42-mediated alteration of
the morphology and dysfunction of mitochondria. Chlorproma-
zine significantly inhibited the Ab1–42-mediated morphological
alteration of mitochondria. Elongated, thread-like HSP60 staining
shapes like those seen in vehicle treatments were observed, while
the co-treatment of the antagonist receptor for advanced glyca-
tion endproducts (RAGE, known receptor for Ab1–42), along with
Figure 2. Functional assays for mitochondria in AbPP/PS1 mice brains and Ab1–42-treated HT22 cell line. Four types of mitochondrial
functional assays: MTT (A); ROS level (B); ATP generation (C) and TMRM intensity (D) were assessed in vehicle or 5 mMA b1–42-treated HT22 cells. MTT
assay were measured after 24 h of Ab treatment, other assays were after 6 h of Ab treatment (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0034929.g002
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mitochondrial morphological damage, we utilized a computer-
based analysis that calculated form factor (FF; mitochondrial
shape) and aspect ratio (AR; mitochondrial length) using the
Image J program.
A quantification of the alteration of mitochondrial morphology
was performed and both parameters were significantly rescued
in cholopromazine+Ab1–42 treatment, but not in mRAGE IgG+
Ab1–42 (Fig. 3B).
In addition to the morphological results, the mitochondrial
functions were also rescued by a co-treatment of chlorpromazine
with Ab1–42 (Fig. 3C–F). Significantly increased ATP generation
and mitochondria membrane potential, concomitant with signif-
icantly decreased ROS generation, were detected after cholopro-
mazine co-treatment with Ab1–42. The MTT activity was also
increased by cholorpromazine co-treatment, however, not on a
significant level. Taken together, the endocytosis blocker success-
fully inhibited Ab1–42-induced mitochondrial impairments in both
morphology, and function.
Mitochondria-targeting Ab1–42 caused deleterious
alteration in mitochondria morphology
As we confirmed that exogenous Ab1–42 needs to enter into the
intracellular compartment to elicit the deterioration of mitochon-
drial morphology and function, an examination was conducted to
learn whether the direct accumulation of Ab1–42 in mitochondria
leads to morphological alteration and functional impairments in
mitochondria in a way that is similar to that observed in the
exogenous Ab1–42 treatment. A DNA construct of Ab1–42 with a
mitochondria-targeting sequence (mito Ab1–42) was created and
transfected into HT22 cells for 12 h (Fig. S1). The specific
targeting and accumulation of mito Ab1–42 was observed in the
mitochondrial compartment, not in cytosol, using immunoblot
analysis with 6E10 (an antibody specific to the amino acid residue
1–16 of Ab, Fig. 4A). The selective nature of subcellular
fractionations was confirmed by antibodies to the compartment-
selective markers: TOM20 (mitochondria specific), GADD153
(ER specific) and b-actin (cytosol specific). An EM image of
mitochondria in mito Ab1–42-transfected cells for 12 h showed the
drastic morphological alteration of mitochondria, compared with
the mitochondria in mock control, which appeared swollen and
suffering from the disappearance of the inner mitochondrial
membrane and invisible cristae (Fig. 4B). These morphological
phenomena are similar to the mitochondrial morphology changes
obtained in AD mouse models. Additionally, confocal microscopy
using immunofluorescence with antibodies to HSP60 (as a
mitochondrial marker) confirmed the deleterious alteration of
mitochondria in mito Ab1–42-transfected cells for 12 h (Fig. 5A).
HSP60 staining showed shorter, less elongated and cloudy
mitochondria in mito Ab1–42-transfected cells, compared with
the mitochondria observed in vehicle-transfected cells. The
efficiency of mito Ab1–42-transfection was visualized through the
co-transfection of YFP, distinguishing mito Ab1–42-transfected cells
from non transfected cells with mito Ab1–42 using green YFP
staining. The quantification parameters for mitochondria shapes,
FF and AR, also proved the significant deterioration of
mitochondrial morphology in mito Ab1–42-transfected cells, but
not in both mock and non-mito Ab1–42-transfected cells (Fig. 5B).
The functional impairment of mitochondria was induced
by mito Ab1–42
Using the functional assays described above, we investigated
whether the mitochondria-specific accumulation of Ab1–42 is
sufficient to cause not only morphological alterations but also
functional impairment in mitochondria in mito Ab1–42-transfected
cells for 12 h. The mitochondria-specific accumulation of mito
Ab1–42 clearly impaired mitochondrial function; significantly
decreasing MTT activity, decreasing ATP generation, increasing
ROS generation and breaking membrane potential (Fig. 5C–F). In
Figs. 5F and 5G, we showed the TMRM intensity results as well as
the staining image to demonstrate that the change in mitochon-
drial dysfunction happened only in mito Ab1–42-transfected cells
(YFP positive), and not in non-transfected cells with mito Ab1–42
(YFP negative).
Apoptosis was induced by mitochondria-specific Ab1–42
accumulation as well as exogenous Ab1–42 treatment
Morphological alteration and functional impairments of mito-
chondria were demonstrated as distinctive phenomena in both
exogenous Ab1–42 treatment and the mitochondria-specific
accumulation of Ab1–42 in HT22 cells. This discovery was
followed by an investigation into whether these mitochondrial
destructions could lead to cellular death through an apoptotic
event. We measured expression level of Bcl-2 and Bax, which is
widely used as the marker to initiate the apoptosis pathway by
triggering cytochrome C release from mitochondria using Western
blotting. When total cell lysates were examined, expression of the
anti-apoptotic protein Bcl-2, decreased significantly during the
mitochondria-specific accumulation of Ab1–42 for 24 h, and
during the exogenous Ab1–42 treatment of HT22 cells while the
Bax expression showed no sign of change in both environments,
which implies that both situations trigger the apoptosis pathway in
the same way (Fig. 6A). A higher mito Ab1–42 expression (4 mgv s
2 mg of mito Ab1–42 transfection) decreased Bcl-2 level, suggesting
that an increased accumulation of mito Ab1–42 down-regulated
Bcl-2. Expression level of Bcl-2 and Bax were assessed by Western
blotting using mitochondrial fraction to confirm previous data.
More dramatic decreased Bcl-2 level and increased Bax level were
observed in condition of mito Ab1–42 expression (Fig. 6B). We also
measured the release of cytochorome C from mitochondria, the
subsequent event of increased Bax/Bcl-2 in the apoptosis pathway,
and detected a significant increase of cytochrome C release during
the mitochondria-specific accumulation of Ab1–42 for 24 h, as well
as during the exogenous Ab1–42 treatment, compared to vehicle
treatment in HT22 cells (Fig. 6C). Finally, a cell viability test
confirmed that the mitochondria-specific accumulation of Ab1–42
for 24 h is a sufficient event to induce cellular death, just as it is in
exogenous Ab1–42 treatment (Fig. 6D and 6E).
Discussion
Ab has attracted a great deal of interest in the field of AD
research, and its influence at the cellular level, and within the
neuronal system, has been the pressing issue to clarify for those
with a goal of diagnostic and therapeutic development. Recent
studies have highlighted the mitochondrial damage induced by Ab
under AD pathological conditions [4,5,7], which raises questions
about the delivery mechanism of Ab-inflicted damage to
mitochondria. It is also vital that we determine whether
mitochondrial impairment by Ab is fatal enough to cause neuronal
death in AD conditions.
One possible cause for mitochondrial dysfunction in AD is the
amyloid precursor protein (APP) [5,19,20]. In both in vitro and in
vivo studies, using APP-expressing HCN-1A cells and an AD SW/
APP (Tg2576) mouse model, respectively, the accumulation of
APP in mitochondria by mitochondrial targeting and the
subsequent transmembrane arrest resulted in mitochondrial
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oxidase activity, reduced respiration-coupled ATP synthesis and
disruption of mitochondrial membrane potential [20]. In this
study, which explored mitochondrial dysfunction by transmem-
brane-arrested APP studies, APP with intact COOH-terminal was
used and arrested as the form of APP observed in the inner
mitochondrial membrane—a finding that precluded Ab produc-
tion. APP was reported to form a ,480 kDa complex with the
translocase of the outer mitochondrial membrane 40 (TOMM40)
import channel in addition to a supercomplex of approximately
620 kDa with both TOMM40 and the translocase of the inner
mitochondrial membrane 23 (TIMM23) import channel, which
are the mechanisms for mitochondrial dysfunction by APP in AD
[21]. However, the mitochondrial influence of Ab1–42 accumula-
tion in mitochondria might be different from the mitochondrial
dysfunction caused by APP through the APP/TOMM40/
TIMM23 complex. Yet, it is unclear whether the mitochondrial-
specific accumulation of physiologically relevant Ab1–42 has a
similar impact on mitochondrial dysfunction. One certainty is that
Ab must enter into the cellular compartment to elicit mitochon-
drial dysfunction, because either the increased production of
extracellular Ab peptide or Ab plaques failed to induce
mitochondrial dysfunction [20,22]. Therefore, mitochondrial
accumulation was regarded as an essential step for Ab-mediated
mitochondrial dysfunction and several reports suggest that
mitochondria are a direct location for Ab accumulation in AD
neurons, proving functional impairments of mitochondria, such as
free radical generation and oxidative damage [13,14]. Questions
remain regarding whether the mitochondrial accumulation of Ab
is a sufficient event to elicit mitochondrial dysfunction or neuronal
death, because mitochondrial Ab accumulation is not the sole
event resulting from the existence of excess Ab in AD conditions.
Other events may occur simultaneously in the presence of Ab,
including the activation of a signaling pathway through receptor
engagement or the destruction of other intracellular organelles
upon cellular entry that may trigger mitochondrial dysfunction
indirectly. Also ionic dyshomeostasis, such as Ca
2+ and Zn
2+, may
synergistically impair mitochondria via pathogenic loop [23].
Our results clearly showed that exogenously treated Ab1–42
enters the intracellular compartment through clathrin-mediated
endocytosis, and mitochondria-specific Ab1–42 accumulation was a
sufficient event to induce not only mitochondrial dysfunction, but
also neuronal death. The receptor for advanced glycation
endproduct (RAGE) is the binding receptor for Ab, and RAGE-
Ab engagement has been reported to modulate diverse signaling
pathways, such as NF-kB, p38 mitogen-activated protein kinase
and ERK1/2 activation [24,25,26,27]. Additionally, RAGE was
reported to mediate the intraneuronal transport of Ab and the
consequent neuronal dysfunction [28]. However, as our Figures 3
and 4 show, blocking RAGE using anti-RAGE IgG failed to
rescue the Ab1–42-mediated mitochondrial disruption in both
morphology and function, suggesting that RAGE-Ab engagement
is not involved in the process of mitochondrial disruption and
dysfunction by Ab. It is possible that the RAGE expression level in
this HT22 cell line might to be too low to mediate the
intraneuronal transport of Ab.
Figure 3. Clathrin-mediated endocytosis blocker inhibited Ab1–42-induced mitochondrial dysfunction. A. Mitochondrial shapes were
identified by immunostaining of HSP60 in vehicle, Ab1–42, chlorpromazine+Ab1–42, mouse anti-RAGE IgG+Ab1–42 treatment in HT22 cells, respectively
(Scale bar: 20 mm). B. Altered mitochondrial shapes are quantified using form factor and aspect ratio (blue: vehicle, red: chlorpromazine+Ab1–42,
green: Ab1–42 in left graph). Four functional assessments of mitochondria are shown, including MTT (C), ROS levels (D), ATP generation (E) and TMRM
intensity (F). * p,0.05, ** p,0.01, *** p,0.001 compared with vehicle, # p,0.05 compared with Ab1–42.
doi:10.1371/journal.pone.0034929.g003
Figure 4. Mitochondria-specific accumulation of mito Ab1–42. A. Western blot analysis showed the mitochondria-specific accumulation of
Ab1–42 with the presence of TOM20, mitochondrial marker and the absence of b-actin. B. EM image of mitochondria in mock and mito Ab1–42-
transfected HT22 cells (yellow scale bar: 2 mm, white scale bar: 1 mm).
doi:10.1371/journal.pone.0034929.g004
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induced by the exogenous treatment of Ab1–42 (ROS level, ATP
generation and TMRM intensity) was rescued when chlorprom-
azine, a clathrin-mediated endocytosis blocker, was co-treated
with Ab1–42, the action failed to fully recover the reduced MTT
activity (Fig. 3C). The co-treatment of chlorpromazine with Ab1–42
produced a mild recovery of MTT activity, but not at a significant
level. The MTT assay measures the cellular activity and viability
within mitochondrial reductase activity. This reductase enzyme is
regulated by many diverse factors because it is very relevant to the
metabolic activity of cells [29]. In addition, disturbing or activating
specific signaling pathways, such as ErbB2, was reported to affect
the mitochondrial reductase activity, which would change the
MTT result [30]. Reduced MTT was induced by both the
intracellular entrance of Ab1–42 followed by mitochondrial Ab1–42
accumulations and the Ab1–42-mediated alteration of the signaling
pathway. Extracellular Ab can facilitate AMPA receptor internal-
ization and NMDA receptor trafficking that may destabilize
intracellular Ca2+ signaling. Also, Ab oligomers can form Ca2+-
permeable pores in the plasma membrane and bind to other cell
surface receptors (for example, LRP, FPRL1, and a7nAChR).
These altered Ca
2+ signaling induced by extracellular Ab can
impair intracellular organelles including mitochondria [31,32,33].
Moreover, even though clathrin-mediated endocytosis serves as
internalization system for trafficking Ab, clathrin-independent
endocytosis can be another possible pathway for Ab internaliza-
tion [34]. For these reasons, blocking the endocytosis of Ab1–42
seems to rescue certain portion of the mitochondrial reductase
activity.
The mitochondria-specific targeting of Ab1–42 was confirmed in
two ways. The Western blot analysis shown in Figure 4 displays
specific Ab immunoreactivity only in the mitochondria fraction
with the presence of Tom20 protein (mitochondrial marker) and
the absence of either GADD153 (ER marker), or b-actin.
Mitochondrial morphology alteration and dysfunction only
occurred in YFP-positive cells, not in YFP-negative cells
(Figs. 5A, 5B and 5F), which suggests that only successfully
transfected mito Ab1–42 cells experienced mitochondrial Ab1–42
accumulation followed by the morphological alteration and
dysfunction of the mitochondria.
Even though diverse variations in the altered expression level of
Bax and Bcl-2 were observed in the apoptosis pathway, including
increases in both [35], a decrease in Bcl-2 and an increase in Bax
and a decrease in Bcl-2 alone [36,37], the typical apoptotic
Figure 5. Mito Ab1–42 induces not only mitochondrial morphological alteration but also functional impairments. A. Immunostaining of
HSP60 and YFP in mock or mito Ab1–42–transfected HT22 cells (white scale bar: 20 mm). B. Quantification of alteration in mitochondrial shape is
presented as form factor and aspect ratio (** p,0.01). Four functional assessments for mitochondria are shown, including MTT (C), ROS levels (D), ATP
generation (E) and TMRM staining (F). G. TMRM intensity is quantified as percent of control. * p,0.05, ** p,0.01, *** p,0.001 compared to mock,
white scale bar in F: 50 mm.
doi:10.1371/journal.pone.0034929.g005
Figure 6. Apoptotic protein expression and cellular death in both exogenous Ab1–42 treatment and mito Ab1–42–transfected cells.
Western blot analysis was performed in both exogenous Ab1–42 treatment and mito Ab1–42–transfected HT22 cells to characterize the expression level
of Ab1–42, Bcl-2, Bax using 6E10, Bcl-2 antibody and Bax antibody (A). Expression level of Bcl-2 and Bax was confirmed in mitochondrial fraction (B).
Different concentrations of mito Ab1–42 DNA constructs were used, 2 mg and 4 mg. Cytochrome C release assay (C) and calcein cell viability assay (D)
were performed in vehicle-treated, exogenous Ab1–42-treated, mock and mito Ab1–42 transfected HT22 cells, respectively (* p,0.05, ** p,0.01
compared with vehicle, # p,0.05 compared to mock).
doi:10.1371/journal.pone.0034929.g006
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2 ratio and followed cytochrome C release from the mitochondria.
Our results clearly show that the increased Bax and decreased Bcl-
2 level followed by cytochrome C release from the mitochondria
was mediated not only by the exogenous treatment of Ab1–42, but
also by the mitochondria-specific accumulation of Ab1–42. These
events ultimately lead to cell death, measured by the calcein
viability test (Fig. 6D and 6E). Calcein-AM could be taken up by
living cells and metabolized by intracellular esterases into the
membrane-impermeable fluorescent calcein that disperses
throughout the entire cytoplasm of the cell, and it is the intensity
of this intracellular fluorescent calcein that indicates cellular
viability. The involvement of CD95/Fas has not been examined in
this study, however, a CD95/Fas-mediated pathway would not be
excluded from future studies as a candidate for a signaling
pathway for mito Ab1–42-mediated cellular death. The existence of
additional influences on mitochondria during the mitochondria-
specific accumulation of Ab1–42 using a mito Ab1–42 DNA
construct is probable, including mitochondrial anterograde/
retrograde transport within the neuron, fission/fusion protein
levels and other signaling pathways that will need to be assessed in
future studies [39,40].
Materials and Methods
Animals and cell cultures
AbPP/PS1 double transgenic mice (AbPP Swedish mutant and
PS1 deletion exon 9 mutant; B6C3Tg (AbPPswe, PSEN1-
dE9)85Dbo/J; stock number 004462) were purchased from
Jackson lab (BarHarbor, ME) and confirmed by genotyping.
The experimental protocol was approved by the Ethics Review
Committee for Animal Experimentation in Seoul National
University. HT22 cells, mouse hippocampal neuronal cell line
(gifted from Dr. David Schubert, Salk Institute), were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; HyClone, Irvi-
ne,CA, USA) supplemented with 10% fetal bovine serum
(HyClone), 0.1 mg/ml penicillin and streptomycin (Sigma,
StLouis, MO) at 37uC in a 5% CO2 incubator.
DNA construct
Created mito Ab sequence were based on pcDNA 3.1/hygro
mammalian expression vector (Invitrogen) and full length APP
cDNA using two sets of primer; 59- AA GGTAC-
CATGTCCGTCCTGACGCCG -39 (mitochondria-targeting se-
quence), 59-AACTC GAGCTACGCTATGACAACACCGCC C
-39 (Ab1–42). Procedure is shown in Figure S1.
Transfection
Transfection of the HT22 cells was performed using Lipofecta-
mine LTX according to the manufacturer’s protocol (Invitrogen,
Carlsbad, CA). Briefly, cells were seeded in 96 well plate for the
mitochondrial functional assay and in 6 well plate for fractionation
of mitochondria. The mito Ab1–42 construct was mixed with
Lipofectamine LTX in OptiMEM (Invitrogen Carlsbad, CA).
After 30 min of incubation, the mixture was added to the cell
culture medium.
Electron microscope analysis
The brain tissues of AbPP/PS1 double transgenic mice and
HT22 cells were fixed overnight in a mixture of cold 2.5%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), and 2%
paraformaldehyde in a 0.1 M phosphate or cacodylate buffer
(pH 7.2) and finally embedded using only epoxy resin. The epoxy
resin-mixed samples were loaded into capsules and polymerized at
38uC for 12 h and 60uC for 48 hours. Thin sections were made
using an ultramicrotome (RMC MT-XL ; RMC Products,
Tucson, AZ, USA) and collected on a copper grid. Appropriate
areas for thin sectioning were cut at 65 nm and stained with
saturated 4% uranyl acetate and 4% lead citrate before
examination with a transmission electron microscope (JEM-
1400; Japan) at 80 Kv.
MTT assay
The medium was aspirated from plates, and 50 ml per well
2.5 mg/ml MTT in phenol red–free medium was added. Plates
were incubated for 2 h at 37uC, followed by the aspiration of the
MTT solution, the addition of 140 ml per well isopropanol to
dissolve formazan crystals, and incubation at 37uC for 30 min.
After incubation, plates were equilibrated to room temperature
(RT) for an additional 20–30 min. Absorbance was measured at
540 nm.
ROS measurement
Levels of hydrogen peroxide were determined using dichloro-
fluorescein diacetate (DCFDA; Invitrogen, Carlsbad, CA). Treat-
ed cells were incubated with 1 mM DCFDA for 30 min and
washed with PBS. Fluorescent signals were captured using a
fluorescence microscope (Olympus, Tokyo, Japan).
Assay for cellular ATP levels
The medium was removed from plates and washed three times
with 50 ml per well PBS. 50 ml per well 1% Triton X-100 (Sigma,
St Louis, MO) was added to lysed cells. 90 ml per well ATP
Determinant Kit reaction solution (Molecular Probes) was added
to 10 ml per well of cell lysate. Plates were agitated for 2 min and
luminescence was measured.
TMRM assay for mitochondrial membrane potential
In depolarized cells, the TMRM dye accumulates in the
mitochondria. Red fluorescence serves as the indicator for
mitochondrial membrane potential. The medium was removed
from plates, and 100 ml per well for 500 nM TMRM (Invitrogen,
Carlsbad, CA) in phenol red–free medium was added. Plates were
incubated for 1 h at 37uC and washed three times with 50 ml per
well PBS. Fluorescent signals were captured using a fluorescence
microscope (Olympus, Tokyo, Japan).
Fractionation of mitochondria
To isolate cytosol and mitochondrial fractions, cells were lysed
by Dounce homogenizer in the buffer containing 20 mM HEPES,
pH 7.5, 250 mM sucrose, 20 mM KCl, 1.5 mM MgCl2,1m M
EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluo-
ride, 0.2 trypsin inhibitory units/ml aprotinin, and 20 mg/ml
leupeptin at 4uC. The cell lysates were centrifuged at 6006g for
10 min to remove unbroken cells and nuclei. The supernatants
were centrifuged at 70006g for 10 min at 4uC and the resulting
pellet was collected as the mitochondrial fraction.
Immunostaining
Cells were fixed for 20 min with 4% paraformaldehyde/PBS
and permeabilized with 0.3% Triton X-100 for 10 min. After
blocking, cells were incubated with primary antibodies (anti-
Hsp60 monoclonal antibody). After PBS washing, cells were
incubated for 1 h at room temperature with fluorescent-linked
secondary antibodies (1:500; Jackson Labs, West Chester, PA,
USA). Cells were counterstained for 5 min with DAPI/PBS
solution. The labeled cells were mounted on glass slides, and then
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FV10i; Olympus, Tokyo, Japan).
Western blotting
For whole cell lysates, cells were washed twice with cold PBS
and directly lysed with 16 sample buffer. For mitochondrial
fractions, cells were fractionated as described previously (Narendra
et al., 2008), and mitochondrial pellets were lysed with 16sample
buffer. 20 mg proteins were separated on 10% Tris-glycine or 10%
Tris-tricine SDS-PAGE. Membranes were incubated with anti-
bodies against the indicated proteins. Enhanced chemilumines-
cence (ECL; GE Healthcare Biosciences, Pittsburgh, PA) was used
for visualization of the signal. The images were captured using a
bioimaging analyzer (LAS-3000; Fuji, Tokyo, Japan) and analyzed
using a Multi-Gauge program (Fuji, Tokyo, Japan). The following
antibodies were used in the study: anti-Tom20 (Santa Cruz
Biotechnology, Inc.), and anti-b-actin (Sigma-Aldrich).
Cytochrome C release
Cytosolic cytochrome C was measured using Cytochorme C
ELISA kit (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. Briefly, 10 mg/ml of each cytosolic fraction was
added to the well of a microtiter plat pre-coated with monoclonal
anti-cytochrome C antibody, followed by adding 100 mlo f
cytochrome C biotin conjugate solution for 1 h at RT. 100 ul of
streptavidin-HRP working solution was added for 30 min at RT.
After 30 min of rocking at RT, 100 ul of stabilized chromogen was
added for 30 min at RT. After 30 min, an equal volume of STOP
solution was added and product was measured on a spectropho-
tometer at 450 nm.
Calcein viability assay
The medium was removed from plates, and 50 ml per well 1 mM
calcein-AM (Molecular Probes) in phenol red–free medium was
added. Plates were incubated for 1 h at 37uC and washed three
times with 50 ml per well PBS. Fluorescence was measured at
excitation and emission wavelengths (ex/em) of 485 nm/530 nm.
Image analyses
Quantitative analysis of cell counting was performed with Image
Pro Plus 5.1 software (Media Cybernetics, Silver Spring, MD). For
morphological analyses of mitochondria, acquired images were
analyzed as described by using IMAGE J (National Institutes of
Health) and Photoshop (Adobe, San Jose, CA).
Statistical analysis
All data was expressed as means 6 SEM. Student t-test was
used for two-group comparisons, and analysis of variance, followed
by Fisher’s LSD post hoc test, which was used to compare three or
more groups using SigmaStat for Windows Version 3.10 (Systat
Software, Inc., Point Richmond,CA). Significance was designated
as P-value,0.05
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